Open Internet by MindsNet

Efficacy of RCHOP in Double Expressor DLBCL

The current standard treatment RCHOP may not be effective for patients with Double Expressor Diffuse Large B-Cell Lymphoma (DLBCL). The addition of HDAC to RCHOP is being explored as a potential solution. The challenge lies in identifying the most effective treatment approach for this specific patient population.

Science, Medicine, Oncology